Hemlibra 30 mg/1 mL. 60 mg/0.4 mL. 105 mg/0.7 mL. 150 mg/1 mL Solution for injection
PDF Leaflet Revision Date: 30 October 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Routine prophylaxis to prevent bleeding in haemophilia A patients.
Dosage (summary)
Loading dose: 3 mg/kg weekly for 4 weeks; Maintenance: 1.5 mg/kg weekly, 3 mg/kg biweekly, or 6 mg/kg every four weeks.
Special Populations
- Paediatric patients
- Elderly patients
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy or breastfeeding.
Key Drug Interactions
- Activated prothrombin complex concentrate (aPCC)
- Recombinant factor VIIa (rFVIIa)
Contraindications
- Hypersensitivity to emicizumab or excipients
Common side effects
- Injection site reactions
- Headache
- Pyrexia
- Arthralgia
- Myalgia
Counselling Points
- Monitor for signs of thrombotic events
- Do not use aPCC unless necessary
- Proper injection technique is crucial
Serious warnings
- Thrombotic microangiopathy
- Thromboembolism
Important Disclaimer
The Hemlibra 30 mg/1 mL. 60 mg/0.4 mL. 105 mg/0.7 mL. 150 mg/1 mL Solution for injection professional information leaflet below is the property of Roche Products and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
